

IN THE CLAIMS:

Please cancel claims 1-63, 66, 67 and 104-131 without prejudice, amend claims 68-74, 76, and 79-103, and add new claims 132-144 as follows.

This listing of claims will replace all prior versions, and listings of the claims in the application.

Listing of the claims

1-63. (Canceled)

64. (Original) A method of inducing a cytostatic effect in a primary or metastasized colorectal, gastric or esophageal cancer cell in an individual who has primary or metastasized colorectal, gastric or esophageal cancer, said method comprising the step of: administering to said individual by substantially continuous infusion, a cytostatically effective amount of an ST receptor ligand per hour for a period of time sufficient to have a therapeutic effect by the cytotoxic effect of the ST receptor ligand, wherein ST receptor ligand molecules bind to ST receptors on the surface of a primary or metastasized colorectal, gastric or esophageal cancer cell in said individual and induces a cystostatic effect in said cells.

65. (Original) A method of inhibiting the proliferation of a primary or metastasized colorectal, gastric or esophageal cancer cell in an individual who primary or metastasized colorectal, gastric or esophageal cancer, said method comprising the step of: administering to said individual by substantially continuous infusion, a cytostatically effective amount of an ST receptor ligand per hour for a period of time sufficient to have a therapeutic effect by the cytostatic effect of the

ST receptor ligand, wherein ST receptor ligand molecules bind to ST receptors on the surface of a primary or metastasized colorectal, gastric or esophageal cancer cell in said individual and inhibits proliferation of said cells.

66-67 (Canceled)

68. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ further comprising the step of administering a therapeutic agent.

69. (Original) The method of claim 68 ~~67~~ wherein the therapeutic agent is 5-fluorouracil.

70. (Original) The method of claim 68 ~~67~~ wherein the therapeutic agent is bleomycin.

71. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor ligand is administered into the circulatory system of said individual.

72. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor ligand is administered intravenously.

73. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor ligand is administered intratumorally.

74. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor ligand is an anti-ST receptor antibody or a fragment thereof.

75. (Original) The method of claim 74 wherein said ST receptor ligand is an anti-ST receptor monoclonal antibody.

76. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor ligand is an ST receptor binding peptide.

77. (Original) The method of claim 76 wherein said ST receptor peptide is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives thereof.

78. (Original) The method of claim 77 wherein said ST receptor binding peptide is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-55 and SEQ ID NO:56.

79. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor binding peptide is initially administered to said individual in a loading dose of at least 0.5 microgram of ST receptor binding peptide per 10 kg. bodyweight of said individual.

80. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said loading dose is .1-10 micrograms ST receptor binding peptide per 10 kg. bodyweight of said individual.

81. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said loading dose is 3-5 micrograms ST receptor binding peptide per 10 kg. bodyweight of said individual.

82. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said loading dose is about 4 micrograms of ST receptor binding peptide per 10 kg. bodyweight of said individual.

83. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor binding peptide is infused into said individual in a dose of .5-8 micrograms of ST receptor binding peptide per 10 kg. bodyweight of said individual per hour.

84. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor binding peptide is infused into said individual in a dose of 1-5 micrograms of ST receptor binding peptide per 10 kg. bodyweight of said individual per hour.

85. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor binding peptide is 20 infused into said individual in a dose of about 3 micrograms of ST receptor binding peptide per 10 kg. bodyweight of said individual per hour.

86. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor binding peptide is infused into said individual for at least 8 hours.

87. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor binding peptide is infused into said individual for at least 12 hours.

88. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor binding peptide is infused into said individual for at least 16 hours.

89. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor binding peptide is infused into said individual for at least 20 hours.

90. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor binding peptide is infused into said individual for at least 24 hours.

91. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor ligand is initially administered to said individual in a loading dose of at least 0.1nM per 10 kg. bodyweight of said individual.

92. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said loading dose is 0.1-10nM of ST receptor ligand per 10 kg. bodyweight of said individual.

93. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said loading dose is 0.5-8nM of ST receptor ligand per 10 kg. bodyweight of said individual.

94. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said loading dose is 1-5nM of ST receptor ligand per 10 kg. bodyweight of said individual.

95. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor ligand is infused into said individual in a dose of .1-10nM of ST receptor ligand per 10 kg. bodyweight of said individual.

96. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor ligand is infused into said individual in a dose of .5-8nM of ST receptor ligand per 10 kg. bodyweight of said individual.

97. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor ligand is infused into said individual in a dose of 1.5nM of ST receptor ligand per 10 kg. bodyweight of said individual.

98. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor ligand is infused into said individual for at least 8 hours.

99. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor ligand is infused into said individual for at least 12 hours.

100. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor ligand is infused into said individual for at least 16 hours.

101. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor ligand is infused into said individual for at least 20 hours.

102. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ wherein said ST receptor ligand is infused into said individual for at least 24 hours.

103. (Currently Amended) The method of claim 64 or 65 ~~64, 65, 66 or 67~~ further comprising administering calcium to said individual.

104-131 (Canceled)

132. (New) The method of claim 64 wherein at least 0.1-10nM of an ST receptor ligand per 10 kg. bodyweight of said individual are administered per hour for at least 6 hours, and a therapeutic pharmaceutical composition that comprises components which target ST receptor for delivery of a therapeutic agent is further administered to said individual.

133. (New) The method of claim 132 wherein said therapeutic pharmaceutical composition comprises a conjugated composition that comprises an ST receptor binding moiety and an active moiety, said active moiety is a therapeutic agent.

134. (New) The method of claim 133 wherein said ST receptor ligand is an anti-ST receptor antibody or a fragment thereof.

135. (New) The method of claim 134 wherein said ST receptor ligand is an anti-ST receptor monoclonal antibody.

136. (New) The method of claim 133 wherein said ST receptor binding moiety is a peptide.

137. (New) The method of claim 133 wherein said ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives thereof.

138. (New) The method of claim 133 wherein said therapeutic agent is radioactive.

139. (New) The method of claim 138 wherein said therapeutic agent is selected from the group consisting of: ⁴³K, ⁵²Fe, ⁵⁷Co, ⁶⁷Cu, ⁶⁷Ga, ⁶⁸Ga, ⁷⁷Br, ⁸¹Rb, ^{81m}Kr, ^{87m}Sr, ^{99m}Tc, ¹¹¹In, ^{113mTl}, ¹²³I, ¹²⁵I, ¹²⁷Cs, ¹²⁹Cs, ¹³¹I, ¹³²I, ¹⁹⁷Hg, ²⁰³Pb, ²⁰⁶Bi, ⁴⁷Sc, ⁶⁷Cu, ⁹⁰Y, ¹⁰⁹Pd, ¹²³I, ¹²⁵I, ¹³¹I,

¹⁸⁶Re, ¹⁸⁸Re, ¹⁹⁹Au, ²¹¹At, ²¹²Pb, ²¹²B, ³²P and ³³P, ⁷¹Ge, ⁷⁷As, ¹⁰³Pb, ¹⁰⁵Rh, ¹¹¹Ag, ¹¹⁹Sb, ¹²¹Sn, ¹³¹Cs, ¹⁴³Pr, ¹⁶¹Tb, ¹⁷⁷Lu, ¹⁹¹Os, ^{193M}Pt and ¹⁹⁷Hg.

140 (New) The method of claim 133 wherein said therapeutic agent is radiostable.

141 (New) The method of claim 133 wherein said therapeutic agent is selected from the group consisting of: compounds that cause cell death, compounds that inhibit cell division, and compounds that induce cell differentiation.

142 (New) The method of claim 133 wherein said therapeutic agent is selected from the group consisting of: chemotherapeutics, toxins and radiosensitizing agents.

143 (New) The method of claim 133 wherein said therapeutic agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, *Pseudomonas* exotoxin, diphtheria toxin, *Clostridium perfringens* phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, nitroimidazole, metronidazole and misonidazole.

144. (New) The method of claim 132 wherein said therapeutic agent is a nucleic acid molecule.